News | November 01, 2023
Ajanta Pharma posts Q2 FY24 consolidated PAT at Rs. 195.30 Cr
Ajanta Pharma has reported total income of Rs. 1049.77 crores during the period ended September 30, 2023
Ajanta Pharma has reported total income of Rs. 1049.77 crores during the period ended September 30, 2023
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
India is following a holistic and inclusive approach in alignment with the vison of Universal Health Coverage and the resolute commitment to ‘leave no one behind
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
The initiative will focus on advocating for cleaner air
2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines
The companies plan to start a pivotal Phase 3 trial in the coming months
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
The company expects that this development could improve the strength of its application to the FDA for new drug approval
Subscribe To Our Newsletter & Stay Updated
